Vassilios Papadakis

发表

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

Günter Schreier, Ruth Ladenstein, Henrik Schroeder, 2017, The Lancet. Oncology.

Risk stratification of high‐risk metastatic neuroblastoma: A report from the HR‐NBL‐1/SIOPEN study

Ruth Ladenstein, Gudrun Schleiermacher, Ulrike Pötschger, 2018, Pediatric blood & cancer.